Pentadecapeptide comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-08-22. Where a claim depends on a specific study, the study is described rather than over-claimed.
Several mechanisms have been proposed to explain the activity observed in animal models. The most frequently cited involve signaling through vascular endothelial growth factor receptor 2 and modulation of the nitric oxide system. Researchers have also described interactions with protective pathways in the gut lining. These proposed mechanisms appear in the literature as hypotheses supported by preclinical observations, not as confirmed pathways in humans. The precise way the peptide produces its reported effects, and whether those effects carry across species, remain areas of active and unresolved investigation.
BPC-157 is a synthetic pentadecapeptide, meaning it consists of fifteen amino acids joined in a single chain. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, a fragment corresponding to part of a larger protein found in human gastric juice. The peptide was first described in the 1990s by researchers in Zagreb who were studying gastric protective factors. It is not a naturally circulating hormone; it is a laboratory-made fragment derived from a stomach protein. The name is an abbreviation of body protection compound, with the number referring to the fragment's position in the source protein.
Most published work on BPC-157 comes from animal experiments rather than controlled human trials. Rodent models have examined its effects on gastrointestinal lesions, tendon and ligament injury, and blood vessel formation. These studies are often small and originate from a limited number of research groups, which affects how broadly the findings can be generalized. No large randomized human trial has been reported in the peer-reviewed literature. Discussion of the compound therefore rests largely on preclinical data, and questions about its effects in people remain open rather than settled.
Early work on this family of molecules examined fractions of human gastric juice, where a larger protein was reported to protect gastrointestinal tissue in animal models. BPC 157 was designed as a shorter, more stable fragment of that protein and then studied on its own. The peptide itself is not a normal dietary component and is not present in the human body in meaningful quantities. Descriptions of its origin therefore refer to the research lineage of a laboratory molecule rather than to an endogenous or nutritional substance.
The sequence contains an unusually high proportion of proline and glycine, which limits regular secondary structure and contributes to solubility in aqueous media. The compound dissolves readily in water and in normal saline. Because it is a peptide, digestive enzymes are expected to break it down if it is swallowed, a consideration that influences the routes of administration used in animal experiments. Detailed conformational data remain limited, and published structural models are largely computational.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic pentadecapeptide | Composed of fifteen amino acid residues |
| Amino acid sequence | Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val | Single-letter form GEPPPGKPADDAGLV |
| Original source | Fragment of a protein in human gastric juice | First characterized in the 1990s |
| Number in name | 157 | Refers to the fragment's position in the source protein |
| Human trial evidence | Limited | Preclinical rodent data predominate |
Most published reports describe experiments in rodents rather than in people. These studies examine outcomes in tendons, ligaments, bone, stomach lining, and intestinal tissue. In rat and mouse models, a frequently reported effect is faster healing or reduced damage. Sample sizes are usually small, and a substantial share of the work originates from a small number of research groups. Independent replication is limited, so how far the findings extend to humans remains an open question.
Proposed mechanisms in the literature involve the nitric oxide system, vascular endothelial growth factor signaling, and epidermal growth factor receptor pathways. Some studies report changes in blood vessel formation or in inflammatory mediators, while others describe interactions with nervous tissue. Much of this evidence rests on molecular markers in cultured cells or animal models. Whether the same pathways operate the same way in humans has not been established. Authors therefore tend to describe mechanisms as hypothetical rather than settled.
Long-term storage of the dry powder is typically described at minus twenty degrees Celsius or colder, while shorter holding periods may use ordinary refrigeration. Repeated warming and cooling cycles are discouraged because they stress the material and can promote aggregation or loss. Light exposure and residual moisture are both treated as avoidable sources of degradation, and working aliquots are often prepared to limit how many times a container is opened. Sealed vials with a desiccant are the usual container.
Quality assessment rests on two separate questions: whether the chain is the intended one, and how much of the sample is that chain. Reverse-phase high-performance liquid chromatography with ultraviolet detection is the standard purity measurement, while mass spectrometry confirms identity through the observed molecular mass. Amino acid analysis and sequence verification provide further checks. A reported purity percentage describes the proportion of the sample represented by the main peak, not the amount of peptide by mass, since counter-ions and water make up part of any lyophilized lot.
In its usual supplied form, the peptide is a white to off-white lyophilized powder that dissolves readily in water and in aqueous buffers. Powder keeps far longer than solution, so material is normally shipped and stored dry, then dissolved only when needed. Once in solution, the chain is subject to hydrolysis and the liquid supports microbial growth, and practical guidance generally treats the dissolved form as short-lived. Containers should stay sealed and desiccated, because the powder takes up moisture from air.
By the late 19th century, semisynthetic vanillin derived from the eugenol found in clove oil was commercially available. Synthetic vanillin became significantly more available in the 1930s, when production from clove oil was supplanted by production from the lignin-containing waste produced by sulfite pulping for preparing wood pulp for the paper industry. By 1981, a single pulp and paper mill in Thorold, Ontario, supplied 60% of the world market for synthetic vanillin. However, subsequent developments in the wood pulp industry have made its lignin wastes less attractive as a raw material for vanillin synthesis. Today, approximately 15% of the world's production of vanillin is still made from lignin wastes, while approximately 85% is synthesized in a two-step process from the petrochemical precursors guaiacol and glyoxylic acid. Beginning in 2000, Rhodia began marketing biosynthetic vanillin prepared by the action of microorganisms on ferulic acid extracted from rice bran. This product, sold at USD$700/kg under the trademarked name Rhovanil Natural, is not cost-competitive with petrochemical vanillin, which sells for around US$15/kg. However, unlike vanillin synthesized from lignin or guaiacol, it can be labeled as a natural flavoring.
== Effects == T3 increases the basal metabolic rate and, thus, increases the body's oxygen and energy consumption. The basal metabolic rate is the minimal caloric requirement needed to sustain life in a resting individual. T3 acts on the majority of tissues within the body, with a few exceptions including the spleen. It increases the synthesis and activity of the Na+/K+-ATPase (which normally constitutes a substantial fraction of total cellular ATP expenditure) without disrupting transmembrane ion balance. In general, it increases the turnover of different endogenous macromolecules by increasing their synthesis and degradation.
==== Asia ==== In Hong Kong, diamorphine is regulated under Schedule 1 of Hong Kong's Chapter 134 Dangerous Drugs Ordinance. It is available by prescription. Anyone supplying diamorphine without a valid prescription can be fined $5,000,000 (HKD) and imprisoned for life. The penalty for trafficking or manufacturing diamorphine is a $5,000,000 (HKD) fine and life imprisonment. Possession of diamorphine without a license from the Department of Health is illegal with a $1,000,000 (HKD) fine and seven years of jail time.
== Attenuation in eukaryotes == Although an attenuation mechanism that involves translation while transcription is ongoing, like to the mechanism for the trp operon (and some other amino acid biosynthetic operons), would not work in eukaryotes, there is evidence for attenuation in Eukaryotes. Research conducted on microRNA processing provides evidence of eukaryotic attenuation; after co-transcriptional endonucleolitical cleavage by Drosha 5'->3' exonuclease XRN2 may terminate further transcription by torpedo mechanism.
Sources: en.wikipedia.org
=== Clinical trials === A phase II study was conducted comparing the safety and efficacy of omadacycline to linezolid for the treatment of complicated skin and skin structure infections. Patients were randomized at 11 sites in the US to receive either omadacycline 100 mg intravenously once daily with an option to transition to 200 mg orally once daily or linezolid 600 mg intravenously twice daily with an option to transition to 600 mg orally twice daily. The results indicated that omadacycline is well tolerated and has the potential to be an effective treatment in patients with complicated skin and skin structure infections. In June 2013, the US Food and Drug Administration (FDA) designated the intravenous and oral formulations of omadacycline as a qualified infectious disease product in the treatment of acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia. A 650-patient phase III registration study comparing omadacycline to linezolid for the treatment of acute bacterial skin and skin structure infections began in June 2015. Omadacycline met the primary efficacy endpoint of early clinical response with statistical non-inferiority (10% margin) compared to linezolid, and was generally safe and well tolerated. The most common treatment-emergent adverse events were gastrointestinal side effects (18.0% for omadacycline vs. 15.8% for linezolid). A 750-patient phase III study comparing omadacycline to moxifloxacin for the treatment of community-acquired bacterial pneumonia began in November 2015.
=== Molecular target for epilepsy therapy === The noncompetitive AMPA receptor antagonists talampanel and perampanel have been demonstrated to have activity in the treatment of adults with partial-onset seizures, indicating that AMPA receptor antagonists represent a potential target for the treatment of epilepsy. Perampanel (trade name: Fycompa) received Marketing Authorisation Approval by the European Commission for the treatment of partial epilepsy on July 27, 2012. The drug was approved in the United States by the Food and Drug Administration (FDA) on October 22, 2012. As has been the case for most recently developed AEDs (AntiEpilectic Drugs) including pregabalin, lacosamide and ezogabine, the FDA recommended that perampanel be classified by the Drug Enforcement Administration (DEA) as a scheduled drug. It has been designated as a Schedule 3 controlled substance. Decanoic acid acts as a non-competitive AMPA receptor antagonist at therapeutically relevant concentrations, in a voltage- and subunit-dependent manner, and this is sufficient to explain its antiseizure effects. This direct inhibition of excitatory neurotransmission by decanoic acid in the brain contributes to the anticonvulsant effect of the medium-chain triglyceride ketogenic diet. Decanoic acid and the AMPA receptor antagonist drug perampanel act at separate sites on the AMPA receptor, and so it is possible that they have a cooperative effect at the AMPA receptor, suggesting that perampanel and the ketogenic diet could be synergistic.
When SWAPO's executive committee proved unable to suppress the PLAN revolt, the Zambian National Defence Force (ZNDF) mobilised several army battalions and attacked the camps held by the mutineers, rounding up an estimated 1,800 PLAN dissidents. SWAPO's Secretary for Information, Andreas Shipanga, was found responsible by the Zambian government for inciting the revolt. Zambian president Kenneth Kaunda deported Shipanga and several other high-ranking dissidents to Tanzania, while incarcerating the others at remote army facilities. Sam Nujoma accused them of being South African agents and carried out a purge of the surviving political leadership and PLAN ranks. Forty mutineers were formally sentenced to death by a PLAN tribunal in Lusaka, and hundreds of others were subject to enforced disappearances. Additionally, the heightened tension between Kaunda's government and PLAN resulted in the ZNDF confiscating PLAN arms caches. The fallout from the Shipanga Affair prompted PLAN to relocate its headquarters from Lusaka to Lubango, Angola, at the invitation of the MPLA. It was joined shortly afterwards by SWAPO's political wing, which relocated to Luanda. SWAPO's closer affiliation and proximity to the MPLA may have influenced its concurrent slide to the left; the party adopted a more overtly Marxist discourse, such as a commitment to a classless society based on the ideals and principles of scientific socialism. From 1976 onward, SWAPO considered itself the ideological as well as the military ally of the MPLA.
Sources: en.wikipedia.org
==== Semisynthesis ==== The semisynthesis of steroids often begins from precursors such as cholesterol, phytosterols, or sapogenins. The efforts of Syntex, a company involved in the Mexican barbasco trade, used Dioscorea mexicana to produce the sapogenin diosgenin in the early days of the synthetic steroid pharmaceutical industry.
=== White's Fort === In 1786, White moved to the future site of Knoxville, where he and fellow explorer James Connor built what became known as White's Fort. The site straddled a hill that was bounded by the river on the south, creeks (First Creek and Second Creek) on the east and west, and a swampy declivity on the north. The fort, which originally stood along modern State Street, consisted of four heavily timbered cabins connected by an 8-foot (2.4 m) palisade, enclosing one-quarter acre of ground. White also erected a mill for grinding grain on nearby First Creek. White's Fort represented the western extreme of the so-called State of Franklin, which Tennessee settlers organized in 1784 after North Carolina reneged on its plans to cede its western territory to the federal government. James White supported the State of Franklin, and served as its Speaker of the Senate in 1786. The federal government never recognized the State of Franklin, however, and by 1789, its supporters once again pledged allegiance to North Carolina. In 1789, White, William Blount, and former State of Franklin leader John Sevier, now members of the North Carolina state legislature, helped convince the state to ratify the United States Constitution. Following ratification, North Carolina ceded control of its Tennessee territory to the federal government. In May 1790, the United States created the Southwest Territory, which included Tennessee, and President George Washington appointed Blount the territory's governor.
Medical availability and clinical practice vary across the world due to regional differences in culture and technology. Modern scientific medicine is highly developed and widespread in the Western world, whereas in some low-resource regions—including parts of Africa, the Pacific Islands of Oceania, Southeast Asia, and Latin America—populations often rely more heavily on traditional medicine. These practices consist of decentralized training structures and vary widely in empirical support; consequently, they may lack formal regulatory oversight or robust evidence for clinical efficacy. In the developed world, evidence-based medicine (EBM) is not universally applied in clinical practice; for example, a 2007 survey of literature reviews found that about 49% of medical interventions lacked sufficient evidence to support either benefit or harm. However, medical practitioners who apply an intervention with uncertain efficacy without adequate justification, transparency, or patient consent may violate the bioethical principle of non-maleficence, a core tenet of biomedical ethics historically associated with the Hippocratic Oath, which emphasizes a primary duty to "first, do no harm." In modern clinical practice, physicians and mid-level practitioners such as physician assistants personally assess patients to diagnose, prognose, treat, and prevent disease using clinical judgment. An initial medical encounter with a patient typically begins with a review of the patient's medical history and medical record, followed by a medical interview and a physical examination.
Geheimrat Julius Wilhelm Theodor Curtius (27 May 1857 – 8 February 1928) was professor of Chemistry at Heidelberg University. He published the Curtius rearrangement in 1890/1894 and also discovered diazoacetic acid, hydrazine and hydrazoic acid. In 1882 he carried out the first ever peptide synthesis, creating the N-protected dipeptide, benzoylglycylglycine.
Sources: en.wikipedia.org
It is a chain of fifteen amino acids, referred to as a pentadecapeptide. The sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It corresponds to a fragment of a protein found in human gastric juice.
It is neither a naturally circulating hormone nor an approved medicine in most countries. It is a synthetic peptide fragment used chiefly as a laboratory research material. Its regulatory status varies by jurisdiction, and it is not authorized as a therapeutic product in the United States or the European Union.
Published human evidence is very limited. Most findings come from rodent studies conducted by a small number of groups. As a result, statements about its effects in humans are generally described as uncertain rather than established.
It is a synthetic peptide. Its design was inspired by a fragment of a protein found in human gastric juice, but the fifteen-amino-acid molecule itself is made in a laboratory and is not a normal component of food or of human tissue in appreciable amounts.